Atossa Therapeutics Reports $9.6 Million Net Loss in Q1 2026, Faces Funding Challenges

Atossa Therapeutics, Inc. reported a net loss of $9.6 million for the first quarter of 2026, an increase from the $6.7 million loss recorded in the same period of the previous year. The company's total operating expenses rose to $9.9 million, up from $7.4 million in the first quarter of 2025. This increase was primarily driven by higher research and development costs, which amounted to $4.8 million, reflecting a 15% increase from $4.2 million in the prior year. General and administrative expenses also surged to $5.1 million, a 56% increase from $3.3 million, largely due to increased legal fees associated with ongoing patent litigation.

As of March 31, 2026, Atossa's cash and cash equivalents stood at $31.7 million, down from $41.3 million at the end of 2025. The company reported a working capital of $29.2 million, indicating a decrease in total assets from $47.6 million at the end of 2025 to $37.9 million. The decline in cash reserves and total assets is attributed to the ongoing operational losses and increased spending on clinical trials and related activities for its lead product candidate, (Z)-endoxifen.

In terms of strategic developments, Atossa has been actively engaged in clinical trials for (Z)-endoxifen, which is currently in Phase 2 development for breast cancer treatment. The company has also received FDA designations for (Z)-endoxifen for the treatment of Duchenne muscular dystrophy and McCune-Albright syndrome, which could provide significant market opportunities. Additionally, a reverse stock split was executed on February 2, 2026, to consolidate shares and potentially enhance the stock's marketability.

Operationally, Atossa has not yet established a consistent revenue stream, which raises concerns about its ability to continue as a going concern. The company has indicated that it will need to secure additional capital to fund its operations and clinical trials. Management plans to explore various funding options, including equity sales and short-term borrowings, but acknowledges the uncertainty surrounding these efforts. The company’s future financial health will depend on its ability to successfully navigate these challenges and achieve regulatory approvals for its product candidates.

Looking ahead, Atossa remains focused on advancing its clinical programs and exploring additional therapeutic areas for (Z)-endoxifen. The company anticipates that the results from ongoing trials will inform its future development strategies and regulatory submissions. However, the need for additional capital and the potential impact of macroeconomic conditions on funding availability remain critical factors that could influence the company's operational trajectory in the coming months.